Omeros Corporation
Clinical trials sponsored by Omeros Corporation, explained in plain language.
A biopharmaceutical company developing treatments for inflammatory and complement-mediated diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Every-8-Week shot could simplify PNH treatment Results expected Dec 2026 (estimated)
-
Every-8-Week shot could simplify PNH treatment
Disease control OngoingThis study tests the long-term safety of an experimental drug called OMS906 in people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Participants receive OMS906 as an intravenous infusion every 8 weeks. The goal is to see if this dosing schedule is safe an…
Phase 2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental drug offered to stem cell transplant patients with rare blood disorder
Disease control ApprovedThis program provides narsoplimab, an experimental drug, to patients who develop a serious blood clotting condition called thrombotic microangiopathy after a stem cell transplant. The goal is to offer treatment when no other options are available. Patients must have had a stem ce…
Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC